ROS and NADPH oxidase: Key regulators of tumor vascularisation;ERO, NADPH oxydases et vascularisation des tumeurs

Medecine/Sciences

Volumn 30, Issue 4, 2014, Pages 415-421

  Garrido Urbani, Sarah ^a   Jaquet, Vincent ^a   Imhof, Beat A ^a  

^a UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

NOX1 PROTEIN, HUMAN; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE;

ARTICLE; HUMAN; METABOLISM; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); OXIDATIVE STRESS; PHYSIOLOGY; VASCULARIZATION;

HUMANS; NADPH OXIDASE; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES;

EID: 84900342518     PISSN: 07670974     EISSN: 19585381     Source Type: Journal    
DOI: 10.1051/medsci/20143004016     Document Type: Article

References (43)

1. Folkman J. Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 2007; 6: 273-286.
2. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342.
3. Al-Husein B, Abdalla M, Trepte M, et al. Antiangiogenic therapy for cancer: an update. Pharmacotherapy 2012; 32: 1095-1111.
4. Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature 2011; 473: 298-307.
5. Farnsworth RH, Lackmann M, Achen MG, Stacker SA. Vascular remodeling in cancer. Oncogene 2013; doi: 10.1038/onc.2013.304.
6. Chandel NS, Maltepe E, Goldwasser E, et al. Mitochondrial reactive oxygen species trigger hypoxia-induced transcription. Proc Natl Acad Sci USA 1998; 95: 11715-11720.
7. Bensimon J. Le switch angiogénique ou comment réveiller les cellules tumorales dormantes. Med Sci (Paris) 2012; 28: 1069-1071.
8. Tertil M, Jozkowicz A, Dulak J. Oxidative stress in tumor angiogenesis-therapeutic targets. Curr Pharm Des 2010; 16: 3877-3894.
9. Gregory AD, Houghton AM. Tumor-associated neutrophils: new targets for cancer therapy. Cancer Res 2011; 71: 2411-2416.
10. Creagan ET, Moertel CG, O'Fallon JR, et al. Failure of high-dose vitamin C (ascorbic acid) therapy to benefit patients with advanced cancer. A controlled trial. N Engl J Med 1979; 301: 687-690.
11. Laleu B, Gaggini F, Orchard M, et al. First in class, potent, and orally bioavailable NADPH oxidase isoform 4 (Nox4) inhibitors for the treatment of idiopathic pulmonary fibrosis. J Med Chem 2010; 53: 7715-7730.
12. Bonner MY, Arbiser JL. Targeting NADPH oxidases for the treatment of cancer and inflammation. Cell Mol Life Sci 2012; 69: 2435-2442.
13. Gray SP, Di Marco E, Okabe J, et al. NADPH oxidase 1 plays a key role in diabetes mellitus-accelerated atherosclerosis. Circulation 2013; 127: 1888-1902.
14. Ushio-Fukai M. Redox signaling in angiogenesis: role of NADPH oxidase. Cardiovasc Res 2006; 71: 226-235.
15. Morgan MJ, Liu ZG. Crosstalk of reactive oxygen species and NF-kappaB signaling. Cell Res 2011; 21: 103-115.
16. Bedard K, Krause KH. The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol Rev 2007; 87: 245-313.
17. Guichard C, Pedruzzi E, Fay M, et al. Les Nox/Duox: une nouvelle famille de NADPH oxydases. Med Sci (Paris) 2006; 22: 953-959.
18. Lambeth JD, Kawahara T, Diebold B. Regulation of Nox and Duox enzymatic activity and expression. Free Radic Biol Med 2007; 43: 319-331.
19. Lambeth JD. NOX enzymes and the biology of reactive oxygen. Nat Rev Immunol 2004; 4: 181-189.
20. Gianni D, DerMardirossian C, Bokoch GM. Direct interaction between Tks proteins and the N-terminal proline-rich region (PRR) of NoxA1 mediates Nox1-dependent ROS generation. Eur J Cell Biol 2011; 90: 164-171.
21. Chatterjee S, Feinstein SI, Dodia C, et al. Peroxiredoxin 6 phosphorylation and subsequent phospholipase A2 activity are required for agonist-mediated activation of NADPH oxidase in mouse pulmonary microvascular endothelium and alveolar macrophages. J Biol Chem 2011; 286: 11696-11706.
22. Thakur S, Du J, Hourani S, et al. Inactivation of adenosine A2A receptor attenuates basal and angiotensin II-induced ROS production by Nox2 in endothelial cells. J Biol Chem 2010; 285: 40104-40113.
23. Garrido-Urbani S, Jemelin S, Deffert C, et al. Targeting vascular NADPH oxidase 1 blocks tumor angiogenesis through a PPARalpha mediated mechanism. PLoS One 2011; 6: e14665.
24. Frey RS, Ushio-Fukai M, Malik AB. NADPH oxidase-dependent signaling in endothelial cells: role in physiology and pathophysiology. Antioxid Redox Signal 2009; 11: 791-810.
25. Shinohara M, Shang WH, Kubodera M, et al. Nox1 redox signaling mediates oncogenic Ras-induced disruption of stress fibers and focal adhesions by down-regulating Rho. J Biol Chem 2007; 282: 17640-17648.
26. Shinohara M, Adachi Y, Mitsushita J, et al. Reactive oxygen generated by NADPH oxidase 1 (Nox1) contributes to cell invasion by regulating matrix metalloprotease-9 production and cell migration. J Biol Chem 2010; 285: 4481-4488.
27. Sadok A, Bourgarel-Rey V, Gattacceca F, et al. Nox1-dependent superoxide production controls colon adenocarcinoma cell migration. Biochim Biophys Acta 2008; 1783: 23-33.
28. Kobayashi S, Nojima Y, Shibuya M, Maru Y. Nox1 regulates apoptosis and potentially stimulates branching morphogenesis in sinusoidal endothelial cells. Exp Cell Res 2004; 300: 455-462.
29. Chen F, Qian LH, Deng B, et al. Resveratrol protects vascular endothelial cells from high glucose-induced apoptosis through inhibition of NADPH oxidase activation-driven oxidative stress. CNS Neurosci Ther 2013; 19: 675-681.
30. Ushio-Fukai M, Tang Y, Fukai T, et al. Novel role of gp91(phox)- containing NAD(P)H oxidase in vascular endothelial growth factor-induced signaling and angiogenesis. Circ Res 2002; 91: 1160-1167.
31. Ikeda S, Yamaoka-Tojo M, Hilenski L, et al. IQGAP1 regulates reactive oxygen species-dependent endothelial cell migration through interacting with Nox2. Arterioscler Thromb Vasc Biol 2005; 25: 2295-2300.
32. Ushio-Fukai M. VEGF signaling through NADPH oxidase-derived ROS. Antioxid Redox Signal 2007; 9: 731-739.
33. Schroder K, Schutz S, Schloffel I, et al. Hepatocyte growth factor induces a proangiogenic phenotype and mobilizes endothelial progenitor cells by activating Nox2. Antioxid Redox Signal 2011; 15: 915-923.
34. Ago T, Kitazono T, Ooboshi H, et al. Nox4 as the major catalytic component of an endothelial NAD(P)H oxidase. Circulation 2004; 109: 227-233.
35. Bhandarkar SS, Jaconi M, Fried LE, et al. Fulvene-5 potently inhibits NADPH oxidase 4 and blocks the growth of endothelial tumors in mice. J Clin Invest 2009; 119: 2359-2365.
36. Petry A, Djordjevic T, Weitnauer M, et al. NOX2 and NOX4 mediate proliferative response in endothelial cells. Antioxid Redox Signal 2006; 8: 1473-1484.
37. Mochizuki T, Furuta S, Mitsushita J, et al. Inhibition of NADPH oxidase 4 activates apoptosis via the AKT/apoptosis signal-regulating kinase 1 pathway in pancreatic cancer PANC-1 cells. Oncogene 2006; 25: 3699-3707.
38. Schroder K, Zhang M, Benkhoff S, et al. Nox4 is a protective reactive oxygen species generating vascular NADPH oxidase. Circ Res 2012; 110: 1217-1225.
39. Fried L, Arbiser JL. The reactive oxygen-driven tumor: relevance to melanoma. Pigment Cell Melanoma Res 2008; 21: 117-122.
40. Maraldi T, Prata C, Vieceli Dalla Sega F, et al. NAD(P)H oxidase isoform Nox2 plays a prosurvival role in human leukaemia cells. Free Radic Res 2009; 43: 1111-1121.
41. Peshavariya H, Dusting GJ, Jiang F, et al. NADPH oxidase isoform selective regulation of endothelial cell proliferation and survival. Naunyn Schmiedebergs Arch Pharmacol 2009; 380: 193-204.
42. Azzi S, Gavard J. Vaisseaux sanguins et tumeurs ou l'art du dialogue. Med Sci (Paris) 2014; 30: 408-414.
43. Hasmim M, Messai Y, Zaeem M, Chouaib S. L'hypoxie tumorale: un déterminant clé de la réactivité stromale et de la réponse antitumorale. Med Sci (Paris) 2014; 30: 422-428.